Medical treatment of retinopathy of type-2 diabetes

Ophthalmologica

Volumn 218, Issue 5, 2004, Pages 291-296

  Cunha Vaz, José G ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

Author keywords

Diabetes; Retinal edema; Retinopathy, treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ASTEMIZOLE; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPYRIDAMOLE; DOBESILATE CALCIUM; GLUTAMATE RECEPTOR ANTAGONIST; INSULIN; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; NEUROPROTECTIVE AGENT; PLACEBO; PROTEIN KINASE C INHIBITOR; SORBINIL; THROMBOCYTE SLOWING FACTOR; TICLOPIDINE;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIMARY MEDICAL CARE; PROCESS DEVELOPMENT; RETINA EDEMA; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT INDICATION; VASCULAR FRAGILITY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DISEASE PROGRESSION; GLYCEMIC INDEX; HUMANS; PRACTICE GUIDELINES;

EID: 4444330116     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079469     Document Type: Review

References (29)

1. Fong DS, Ferris FL: Practical management of diabetic retinopathy. Focal Points, American Academy of Ophthalmology, March 2003, Section 3.
2. Skyler JS: Diabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am 1996;25:243-254.
3. Cunha-Vaz JG, Lobo C: Medical therapy of diabetic retinopathy. Exp Ophthalmol 1998;24:1-5.
4. Kinoshita JH: Aldose reductase in the diabetic eye: XLII Edward Johnson memorial lecture. Am J Ophthalmol 1986;102:685-692.
5. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoformselective inhibitor. Diabetes 1997;46:1473-1480.
6. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweitland MA, Lancaster JR, Williamson JR, McDaniel M: Aminoguadine, a novel inhibitor of nitric oxide formation, prevents vascular dysfunction. Diabetes 1992;41:552-556.
7. Lobo C, Bernardes R, Faria de Abreu JR, Cunha-Vaz JG: One year follow-up of blood retinal barrier and retinal thickness alterations in diabetes type 2 subjects with mild nonproliferative retinopathy. Arch Opthalmol 2001;119:1469-1474.
8. Hee MR, Puliafito CA, Duker JS: Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998;105:360-370.
9. Cunha-Vaz, J.G.: Diabetic macular edema. Eur J Ophthalmol 1998;8:127-130.
10. Gardner TW, Eller AW, Friberg TR, et al: Anti-histamines reduce blood-retinal barrier permeability in type I (insulin-dependent) diabetic patients with nonproliferative retinopathy: A pilot study. Retina 1995;15:134-140.
11. Leite, E. Mota, M.C., Faria de Abreu, J.R., Cunha-Vaz, J.G.: Effect of calcium dobesilate on the BRB in early stages of diabetic retinopathy. Int Ophthalmol 1990;14:81-88.
12. Chatuverdi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
13. Klein R, Klein BE, Moss SE, Davis MD, De-Mets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-2871.
14. Klein R, Klein BE, Moss SE, Cruikshanks KJ: Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169-2178.
15. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment on of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329:977-986.
16. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Schichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
17. UK Prospective Diabetes Study Group: Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998;21(suppl 1):S23-S31.
18. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
19. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1998;21(suppl 1):S23-S31.
20. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703:713.
21. UK Prospective Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. BMJ 1998;317:713-720.
22. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-2446.
23. Chew EY, Klein ML, Ferris FL III, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D: Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. ETDRS Report Number 22. Arch Ophthalmol 1996;114:1079-1084.
24. Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy. ETDRS Report Number 8. Ophthalmology 1991;98:757-765.
25. DAMAD Study Group: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: A multicenter randomized controlled clinical trial. Diabetes 1989;38:491-498.
26. TIMAD Study Group: Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990;108:1577-1583.
27. Sorbinil Retinopathy Trial Research Group: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108:1234-1244.
28. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731.
29. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171-179.